Gabapentin
Product Images NDC 10544-011

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 10544-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label (10544 011 30 31722 222 05)

Gabapentin Capsules USP 300mg packaging label from Blenheim Pharmacal, Inc. The label includes dosage information for 30 capsules, with storage instructions to keep at controlled room temperature. The NDC is 10544-011-30, with lot and expiration dates noted.*

FDA Label Image

7d5ebe51-figure-01 (7d5ebe51 Figure 01)

Chemical structure of gabapentin, showing a cyclohexane ring with attached aminomethyl and acetic acid functional groups.*

FDA Label Image

7d5ebe51-figure-02 (7d5ebe51 Figure 02)

Line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks with a 4-week dose titration and a 4-week fixed dose period; the y-axis shows mean pain scores from 0 to 10. Gabapentin group shows a steady decrease in pain scores, whereas placebo remains relatively stable.*

FDA Label Image

7d5ebe51-figure-03 (7d5ebe51 Figure 03)

A line graph depicting mean pain score over seven weeks with data for placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day groups. The x-axis shows weeks, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Both gabapentin groups show decreased pain scores compared to placebo over time.*

FDA Label Image

7d5ebe51-figure-04 (7d5ebe51 Figure 04)

A bar chart showing the percentage of responders at endpoint in two studies. Study 1 compares placebo (PBO) at 12% with Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo (PBO) at 14% with Gabapentin (GBP) 1800 mg at 32% and 2400 mg at 34%. Statistical significance indicators note p < 0.01 and p < 0.001 for GBP groups.*

FDA Label Image

7d5ebe51-figure-05 (7d5ebe51 Figure 05)

A scatter plot comparing percentage differences at various daily doses (600, 900, 1200, 1800 mg) of Gabapentin across three studies labeled as Study a, Study b, and Study c, each represented by different symbols and grouped by dose on the x-axis with percentage difference on the y-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.